About ascendis pharma - ASND
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.
ASND At a Glance
Ascendis Pharma A/S
Tuborg Boulevard 12
Hellerup, Capital Region 2900
| Phone | 45-70-22-22-44 | Revenue | 812.73M | |
| Industry | Pharmaceuticals: Major | Net Income | -257,354,177.91 | |
| Sector | Health Technology | 2025 Sales Growth | 106.618% | |
| Fiscal Year-end | 12 / 2026 | Employees | N/A | |
| View SEC Filings |
ASND Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 15.902 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 212.47 |
| Enterprise Value to EBITDA | -98.82 |
| Enterprise Value to Sales | 16.271 |
| Total Debt to Enterprise Value | 0.077 |
ASND Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 4.388 |
| Total Asset Turnover | 0.591 |
ASND Liquidity
| Current Ratio | 1.037 |
| Quick Ratio | 0.755 |
| Cash Ratio | 0.576 |
ASND Profitability
| Gross Margin | 85.083 |
| Operating Margin | -18.923 |
| Pretax Margin | -31.794 |
| Net Margin | -31.666 |
| Return on Assets | -18.709 |
| Return on Equity | N/A |
| Return on Total Capital | -30.908 |
| Return on Invested Capital | -97.148 |
ASND Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 122.966 |
| Total Debt to Total Assets | 66.928 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 54.34 |